Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

Peptide Database

265 therapeutic peptides with research summaries, clinical findings, and regulatory status.

Showing 1–29 of 29 in MetabolicClear filters
MetabolicFDA Approved

Semaglutide (Ozempic/Wegovy)

A glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin…

Subcutaneous injection (weekly), Oral (daily - Rybelsus)
MetabolicFDA Approved

Tirzepatide (Mounjaro/Zepbound)

A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…

Subcutaneous injection (weekly)
MetabolicIn Clinical Trials

Retatrutide

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…

Subcutaneous injection (weekly)
MetabolicInvestigational

AOD-9604

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…

Subcutaneous injection, Oral
MetabolicFDA Approved

Liraglutide (Saxenda/Victoza)

A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…

Subcutaneous injection (daily)
MetabolicFDA Approved

Exenatide (Byetta/Bydureon)

A synthetic version of exendin-4, a 39-amino acid peptide originally isolated from the saliva of the Gila monster lizard (Heloderma suspectum).…

Subcutaneous injection (twice daily or weekly extended-release)
MetabolicFDA Approved

Glucagon

A 29-amino acid peptide hormone produced by alpha cells of the pancreatic islets of Langerhans. Glucagon acts primarily on hepatocytes via the…

Subcutaneous injection, Intramuscular injection, Intranasal
MetabolicFDA Approved

Pramlintide (Symlin)

A synthetic analog of amylin (islet amyloid polypeptide), a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells.…

Subcutaneous injection (before meals)
MetabolicFDA Approved

Dulaglutide (Trulicity)

A long-acting GLP-1 receptor agonist consisting of a GLP-1 analog covalently linked to a modified human IgG4 Fc fragment via a peptide linker. This…

Subcutaneous injection (weekly)
MetabolicFDA Approved

Lixisenatide (Adlyxin)

A selective GLP-1 receptor agonist derived from exendin-4 with a modified C-terminal tail containing six lysine residues. Lixisenatide has a…

Subcutaneous injection (daily)
MetabolicFDA Approved

Setmelanotide (Imcivree)

A cyclic peptide melanocortin-4 receptor (MC4R) agonist designed to restore MC4R signaling in patients with obesity caused by genetic deficiencies in…

Subcutaneous injection (daily)
MetabolicIn Clinical Trials

Orforglipron

Orforglipron is a non-peptide, oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist designed to overcome the need for injectable…

Oral
MetabolicIn Clinical Trials

Mazdutide

Mazdutide is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist delivered as a synthetic peptide. By co-activating both receptors…

Subcutaneous injection
MetabolicIn Clinical Trials

Survodutide

Survodutide is a dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucagon receptors, formulated as a peptide for subcutaneous…

Subcutaneous injection
MetabolicIn Clinical Trials

CagriSema

CagriSema is a fixed-ratio combination of cagrilintide, an amylin analog, and semaglutide, a GLP-1 receptor agonist, both delivered as peptides via…

Subcutaneous injection
MetabolicIn Clinical Trials

Amycretin

Amycretin is a dual agonist targeting both the amylin and calcitonin receptors, designed as a peptide therapeutic for obesity. Amylin receptor…

Subcutaneous injection
MetabolicIn Clinical Trials

Efinopegdutide

Efinopegdutide is a long-acting dual agonist of the GLP-1 and glucagon receptors, utilizing PEGylation to extend half-life and enable once-weekly…

Subcutaneous injection
MetabolicIn Clinical Trials

Danuglipron

Danuglipron is an oral, non-peptide small-molecule agonist of the GLP-1 receptor developed to provide convenient daily dosing for type 2 diabetes and…

Oral
MetabolicIn Clinical Trials

Ecnoglutide

Ecnoglutide is a long-acting GLP-1 receptor agonist peptide designed for once-weekly subcutaneous administration. It acts by enhancing…

Subcutaneous injection
MetabolicIn Clinical Trials

Cotadutide

Cotadutide is a dual agonist of the GLP-1 and glucagon receptors formulated as a peptide for subcutaneous injection. It is designed to harness…

Subcutaneous injection
MetabolicIn Clinical Trials

Glepaglutide

Glepaglutide is a long-acting GLP-2 receptor agonist peptide developed for the treatment of short bowel syndrome. GLP-2 promotes intestinal growth…

Subcutaneous injection
MetabolicIn Clinical Trials

Apraglutide

Apraglutide is a long-acting glucagon-like peptide-2 (GLP-2) receptor agonist designed to promote intestinal growth and improve absorption in…

Subcutaneous injection
MetabolicFDA Approved

Teduglutide (Gattex)

Teduglutide is a recombinant analogue of human glucagon-like peptide-2 (GLP-2) comprising 33 amino acids with a single amino acid substitution that…

Subcutaneous injection
MetabolicInvestigational

Beinaglutide

Beinaglutide is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist engineered with structural modifications to prolong plasma half-life…

Subcutaneous injection
MetabolicFDA Approved

Albiglutide (Tanzeum)

Albiglutide is a GLP-1 receptor agonist consisting of a tandem repeat of modified human GLP-1 sequences fused to human albumin, creating a protein of…

Subcutaneous injection
MetabolicInvestigational

Taspoglutide

Taspoglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist derived from human GLP-1 with amino acid substitutions designed to…

Subcutaneous injection
MetabolicIn Clinical Trials

Pemvidutide

Pemvidutide is a dual receptor agonist targeting both glucagon-like peptide-1 (GLP-1) and glucagon receptors, designed to combine the insulinotropic…

Subcutaneous injection
MetabolicIn Clinical Trials

Cagrilintide

Cagrilintide is a long-acting amylin analogue engineered with structural modifications to extend half-life and enable once-weekly dosing for the…

Subcutaneous injection
MetabolicInvestigational

Enlicitide

Enlicitide is an investigational peptide agonist designed to modulate metabolic pathways involved in energy balance and glucose homeostasis. Limited…

Subcutaneous injection

All 265 peptides

Complete index, every profile, one click away.

Important Medical Disclaimer

The information provided by the Peptide Association is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified, licensed healthcare provider before beginning any peptide therapy, supplement regimen, or making changes to an existing treatment plan.

Peptide therapies discussed on this site may not be FDA-approved for all listed indications. Individual results vary. The Peptide Association does not prescribe, diagnose, or treat any medical condition. Clinicians in our network are independently licensed practitioners; the Association reviews licensure but does not employ or directly supervise these clinicians.

© 2026 The Peptide Association. All rights reserved. Content on this site is protected under applicable intellectual property laws. HIPAA-compliant infrastructure. The Peptide Association is not a medical practice.